Which radiopharmaceutical is known for its application in lung disease assessment?

F-18 fluoroethyl tyrosine is the radiopharmaceutical recognized for its application in assessing lung diseases, particularly in identifying lung cancer and other related pulmonary conditions. This agent is a derivative of the amino acid tyrosine and is widely used in positron emission tomography (PET) imaging. Its ability to accumulate in malignant tissues makes it particularly valuable in distinguishing tumor activity in the lungs from healthy tissues.

On the other hand, the other options are associated with different applications. HDP oxidronate and MDP medronate are primarily used for bone imaging, targeting areas of increased osteoblastic activity, which is not specific to lung disease. F-18 sodium fluoride is also used for bone scans to detect metastatic disease and does not share the same specificity for lung assessments. Therefore, F-18 fluoroethyl tyrosine stands out as the most suitable choice for evaluating lung pathologies.